217 related articles for article (PubMed ID: 27769062)
21. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
Massimino M; Consoli ML; Mesuraca M; Stagno F; Tirrò E; Stella S; Pennisi MS; Romano C; Buffa P; Bond HM; Morrone G; Sciacca L; Di Raimondo F; Manzella L; Vigneri P
Carcinogenesis; 2014 May; 35(5):1132-43. PubMed ID: 24445143
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine-phosphorylated STAT5 accumulates on podosomes in Hck-transformed fibroblasts and chronic myeloid leukemia cells.
Poincloux R; Cougoule C; Daubon T; Maridonneau-Parini I; Le Cabec V
J Cell Physiol; 2007 Oct; 213(1):212-20. PubMed ID: 17503465
[TBL] [Abstract][Full Text] [Related]
23. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
[TBL] [Abstract][Full Text] [Related]
24. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
25. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.
Watanabe T; Hotta C; Koizumi S; Miyashita K; Nakabayashi J; Kurotaki D; Sato GR; Yamamoto M; Nakazawa M; Fujita H; Sakai R; Fujisawa S; Nishiyama A; Ikezawa Z; Aihara M; Ishigatsubo Y; Tamura T
Cancer Res; 2013 Nov; 73(22):6642-53. PubMed ID: 24242069
[TBL] [Abstract][Full Text] [Related]
26. Leukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding protein.
Huang W; Saberwal G; Horvath E; Zhu C; Lindsey S; Eklund EA
Mol Cell Biol; 2006 Sep; 26(17):6311-32. PubMed ID: 16914719
[TBL] [Abstract][Full Text] [Related]
27. Decreased calpain activity in chronic myeloid leukemia impairs apoptosis by increasing survivin in myeloid progenitors and xiap1 in differentiating granulocytes.
Huang W; Bei L; Hjort EE; Eklund EA
Oncotarget; 2017 Aug; 8(31):50629-50641. PubMed ID: 28881589
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
29. Constitutive activation of SHP2 protein tyrosine phosphatase inhibits ICSBP-induced transcription of the gene encoding gp91PHOX during myeloid differentiation.
Zhu C; Lindsey S; Konieczna I; Eklund EA
J Leukoc Biol; 2008 Mar; 83(3):680-91. PubMed ID: 18089853
[TBL] [Abstract][Full Text] [Related]
30. Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.
Fahrenkamp D; de Leur HS; Küster A; Chatain N; Müller-Newen G
Cell Commun Signal; 2015 Feb; 13():10. PubMed ID: 25885255
[TBL] [Abstract][Full Text] [Related]
31. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
32. Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia.
Konieczna I; Horvath E; Wang H; Lindsey S; Saberwal G; Bei L; Huang W; Platanias L; Eklund EA
J Clin Invest; 2008 Mar; 118(3):853-67. PubMed ID: 18246201
[TBL] [Abstract][Full Text] [Related]
33. Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.
Li Q; Huang Z; Gao M; Cao W; Xiao Q; Luo H; Feng W
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257089
[TBL] [Abstract][Full Text] [Related]
34. Retroviral integration site analysis identifies ICSBP as a collaborating tumor suppressor gene in NUP98-TOP1-induced leukemia.
Gurevich RM; Rosten PM; Schwieger M; Stocking C; Humphries RK
Exp Hematol; 2006 Sep; 34(9):1192-201. PubMed ID: 16939812
[TBL] [Abstract][Full Text] [Related]
35. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.
Grumbach IM; Mayer IA; Uddin S; Lekmine F; Majchrzak B; Yamauchi H; Fujita S; Druker B; Fish EN; Platanias LC
Br J Haematol; 2001 Feb; 112(2):327-36. PubMed ID: 11167825
[TBL] [Abstract][Full Text] [Related]
36. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
37. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
[TBL] [Abstract][Full Text] [Related]
39. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
40. Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo.
Wahiduzzaman M; Ota A; Karnan S; Hanamura I; Mizuno S; Kanasugi J; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Takami A; Hosokawa Y
Cancer Lett; 2018 Oct; 433():117-130. PubMed ID: 29944906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
